A therapeutic strategy based on thyromimetic use, either as single agents or in combination with other drugs, may be effective for the treatment of liver diseases, as NAFLD and NASH are currently devoid of any effective treatment
BPC-157 appears to be an exception in animal studies: it retains biological activity when administered intragastrically in rats and mice, including in colitis and ulcer models
Whether at a clinic, drip bars, or through mobile IV services, the treatment is designed to fit seamlessly into busy schedules
Reduced Glutathione is in fact able to give up its hydrogen (H+), which acts as an acceptor of an electron (e-) coming from reactive oxygen molecules, that is, from free radicals
Beyond effectiveness, improper storage can also raise safety concerns